As of May 31
| +0.25 / +7.49%|
The 2 analysts offering 12-month price forecasts for PDL BioPharma Inc have a median target of 3.75, with a high estimate of 4.00 and a low estimate of 3.50. The median estimate represents a +4.46% increase from the last price of 3.59.
The current consensus among 2 polled investment analysts is to Hold stock in PDL BioPharma Inc. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.